Aggravated Atherosclerosis and Vascular Inflammation With Reduced Kidney Function Depend on Interleukin-17 Receptor A and Are Normalized by Inhibition of Interleukin-17A

Effective therapy of atherosclerotic complications in patients with chronic kidney disease (CKD) is an unmet clinical need. Cardiovascular events are the most common cause of death. At a glomerular filtration rate ≤60 ml/min, these events are increased also after correction for common risk factors....

Descripción completa

Detalles Bibliográficos
Autores principales: Nordlohne, Johannes, Helmke, Alexandra, Ge, Shuwang, Rong, Song, Chen, Rongjun, Waisman, Ari, Haller, Hermann, von Vietinghoff, Sibylle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058956/
https://www.ncbi.nlm.nih.gov/pubmed/30062194
http://dx.doi.org/10.1016/j.jacbts.2017.08.005
Descripción
Sumario:Effective therapy of atherosclerotic complications in patients with chronic kidney disease (CKD) is an unmet clinical need. Cardiovascular events are the most common cause of death. At a glomerular filtration rate ≤60 ml/min, these events are increased also after correction for common risk factors. Previous studies have reported enhanced vascular inflammation in mice and recently also in humans. Our current data show, in a mouse model of atherosclerosis in moderate renal impairment, that interleukin-17 receptor A is instrumental in this condition, and blockade of this pathway can normalize arterial inflammation even in advanced atherosclerosis.

Ejemplares similares